LOG IN
Analysis
Featured Analysis
Articles by Category
Current Editions
Data Graphics
Discovery & Translation
Hot Topics
BioCentury Podcasts
Special Reports & Presentations
White Papers
BCIQ Data
BCIQ
Company Profiles
Product Profiles
Target Profiles
Financial Dashboards
Events
All Events
East-West Healthcare Reception
Bio€quity Europe
Grand Rounds — U.S.
Grand Rounds — Europe
China Healthcare Summit
East-West Biopharma Summit 2026
Bio€quity Europe 2026
Podcast: The BioCentury Show
Podcast: BioCentury This Week
Webinars
My Workspace
About BioCentury
Management
Analysts & Research Team
Scientific Advisory Board
Contact
Contact Us
Forgot Password
Request a Subscription
Sponsorship & Branding Inquiry
Media Kit
Request BioCentury's BCIQ Brochure
Customer Resource Center
Career Opportunities
Request a Trial
Company Profiles
Target Profiles
Product Profiles
Latest Articles
Commentaries
Deals
Distillery
Emerging Companies
Finance
Politics, Policy & Law
Product Development
Regulation
Targets & Mechanisms
Tools & Techniques
Company Profiles
Target Profiles
Product Profiles
China Healthcare Summit
Bio€quity Europe
Explore BCIQ profiles by entering a company name.
REQUEST A FREE TRIAL
Overview
Pipeline
Deals
Financings
Earnings Summary
Stock Summary
Articles
Matinas Biopharma Holdings Inc.
Headquarters:
Bedminster, NJ, United States
Website:
http://www.matinasbiopharma.c...
Year Founded:
2011
Status:
Public
Industry Sector:
HealthTechnology
CEO:
Jerome D. Jabbour
Number Of Employees:
7
Enterprise Value:
$-1,958,427
PE Ratio:
-0.12
Exchange/Ticker 1:
NYSE-A:MTNB
Exchange/Ticker 2:
N/A
Latest Market Cap:
$3,153,900
BioCentury
|
Feb 7, 2025
Management Tracks
Biondi becomes managing partner at Flagship
Plus: New CMOs at Epitopea and Cadrenal
Read More
BioCentury
|
Jan 13, 2023
Deals
J.P. Morgan deal wrap: European buyers, RNA and gene editing in spotlight
Takeouts feature CVRs to balance regulatory risk, while appetite for research collaborations remains strong in newer modalities
Read More
BioCentury
|
Sep 21, 2022
Management Tracks
Sharma and Lippman join Alnylam C-suite
Plus Shah now COO at Precigen and updates from Carmot, Evozyne, Matinas, Maxwell and more
Read More
BioCentury
|
Apr 12, 2022
Product Development
AACR data hint BioNTech on path to clearing two industry hurdles
Early data for BNT211 show German biotech’s progress in applying CAR T cells to solid tumors, finding an effective application for cancer vaccines
Read More
BioCentury
|
Dec 7, 2021
Management Tracks
Biohaven names Coric chair, Buten CFO
Plus: Mutamba joins Arrakis as CBO and updates from Goldfinch, Kymera, AnHeart and more
Read More
BioCentury
|
Dec 3, 2020
Management Tracks
Management Tracks: Zai taps Sandler as cancer head, plus moves at FibroGen, Arena, Samumed, Avita, Mersana, Frequency, Matinas, NeuBase, Allena and RA
Zai Lab Ltd. (NASDAQ:ZLAB; HKEX:9688) hired Alan Sandler as president, head of global development, oncology, a newly created position. Sandler was SVP and global head of product development oncology
Read More
BioCentury
|
Feb 25, 2019
Company News
Management tracks: Viriom, Matinas, Atreca
Read More
BioCentury
|
Jan 19, 2018
Clinical News
Matinas' MAT2203 meets in Phase IIa for mucocutaneous candidiasis
Read More
BioCentury
|
Jul 13, 2017
Clinical News
Matinas reports Phase II data of MAT2203 for vulvovaginal candidiasis
Read More
BioCentury
|
Apr 19, 2017
Company News
Management tracks
Read More
Items per page:
10
1 - 10 of 27